10-Q: Elevance Health Q1 2026 Earnings: Revenue Up, Net Income Down

Elevance Health reported a 1.5% increase in total operating revenue for Q1 2026, reaching $49.5 billion, though net income saw a 19.2% decrease to $1.76 billion.

Summary

• Elevance Health's total operating revenue for the first quarter of 2026 was $49.5 billion, a 1.5% increase compared to the same period in 2025.
• Net income for the quarter was $1.76 billion, a decrease of 19.2% from $2.18 billion in the prior year's first quarter.
• Diluted earnings per share (EPS) decreased by 16.8% to $8.00 from $9.61 in the first quarter of 2025.
• The company experienced a decline in total medical membership by 0.9% to 45.4 million members, primarily due to Medicaid redeterminations and decreases in Medicare Advantage and Employer Group Risk-Based businesses.
• Operating expenses increased by 3.9% to $47.9 billion, largely due to a loss contingency accrual for Medicare Advantage risk adjustment data and costs associated with the Operating Model Transformation Program.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant decrease in net income and EPS, despite revenue growth, driven by increased operating expenses and a decline in key membership segments.

Positives

• Total operating revenue increased by 1.5% to $49.5 billion, driven by premium rate increases and growth in CarelonRx product revenues.
• Net investment income increased by 29.7% to $765 million.
• Net losses on financial instruments decreased significantly by 83.2% to $78 million.
• Operating cash flow saw a substantial increase of $3.3 billion to $4.3 billion.
• Vision membership increased by 10.7% to 11.98 million members.
• Approximately 59% of Medicare Advantage members are enrolled in plans rated at least 4.0 Stars or higher for 2026 ratings, an improvement from 40% for 2025 ratings.

Negatives

• Shareholders' net income decreased by 19.2% to $1.76 billion.
• Diluted earnings per share (EPS) decreased by 16.8% to $8.00.
• Total medical membership declined by 0.9% to 45.4 million, with notable decreases in Medicaid (-4.6%) and Medicare Advantage (-15.8%).
• Operating expenses increased by 3.9% to $47.9 billion, driven by a significant loss contingency accrual and transformation program costs.
• The benefit expense ratio increased due to elevated medical cost trends in the Medicaid business.
• CarelonRx experienced a 4.3% decrease in quarterly adjusted scripts.
• Carelon Services saw a 6.6% decrease in consumers served.

Risks

• Potential for increased medical cost trends due to changes in utilization, unit costs, regulatory changes, aging population, and health status of members.
• Regulatory uncertainties and potential impacts from federal and state legislation, including provisions related to Medicaid, Medicare, and pharmacy benefit managers.
• The company is contesting a civil lawsuit filed by the DOJ alleging false certifications for risk-adjustment purposes under Medicare Part C.
• CMS has notified the company of its intent to impose intermediate sanctions for alleged noncompliance with Medicare Advantage risk adjustment data submission requirements, with a potential accrual of $935 million for identified exposure.
• The company faces ongoing litigation related to Blue Cross Blue Shield Antitrust claims, with follow-on cases still pending.
• Cyber-attacks or other privacy or data security incidents could adversely affect the company.
• Failure to effectively maintain and modernize information systems or for these systems to operate as intended.
• Potential for negative impacts from changes in economic and market conditions on liquidity and investment portfolios.
• Intense competition and the need to adapt to industry changes and develop strategic growth opportunities.
• Risks associated with Medicare and Medicaid programs, including non-compliance with complex regulations and potential negative changes in Star Ratings.
• Costs and liabilities associated with litigation, government investigations, audits, or reviews.
• Potential for impairment of intangible assets if future results do not support goodwill and other intangible assets.

Future Outlook

The company expects the Public Exchange to be influenced by policy and regulatory changes. Enhanced PTCs expired on December 31, 2025, which may negatively impact Individual market enrollment due to increased coverage premiums. The company believes its cash on hand, operating cash receipts, investments, and available credit facilities will be adequate to fund expected cash disbursements over the next twelve months.

Management Comments

• Elevance Health is a health company with the purpose of improving the health of humanity.
• We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 45.4 million medical members through our affiliated health plans as of March 31, 2026.
• We strive to price our health benefit products consistent with anticipated underlying medical cost trends.
• We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.
• While the Company is working with CMS to complete these steps to reach a resolution that avoids the imposition of sanctions or other remedies, there can be no assurance that such a resolution can be achieved.
• We believe that cash on hand, future operating cash receipts, investments and funds available under our commercial paper program, our 5-Year Facility and borrowings available from the FHLBs will be adequate to fund our expected cash disbursements over the next twelve months.

Industry Context

StockSavvy.ai notes that Elevance Health's Q1 2026 results reflect ongoing industry pressures, including rising medical costs, regulatory shifts, and membership fluctuations, particularly in the Medicaid segment due to eligibility redeterminations. The company's strategic initiatives, such as the Operating Model Transformation Program, aim to streamline operations and leverage technology, aligning with broader industry trends towards efficiency and digital transformation.

Comparison to Industry Standards

• Elevance Health's revenue growth of 1.5% in Q1 2026 is moderate compared to the overall healthcare payer industry, which has seen varied growth rates depending on segment mix and market conditions.
• The decline in net income and EPS is a concern, as many large health insurers have reported stable or growing profitability in recent periods, though specific segment performance can vary.
• The 0.9% decrease in total medical membership is consistent with trends observed across the industry, particularly the impact of Medicaid redeterminations and shifts in the ACA marketplace.
• The increase in operating expenses, driven by a loss contingency accrual and transformation costs, is a significant factor impacting profitability. Many competitors are also investing heavily in technology and operational efficiency, which can lead to increased short-term expenses.
• The company's benefit expense ratio, while increasing, remains within a range typical for large health insurers, though the specific drivers (Medicaid costs) are a key area of focus for the industry.

Legal Proceedings

• Elevance Health is a defendant in the consolidated In re Blue Cross Blue Shield Antitrust Litigation, with follow-on cases pending.
• The company is contesting a civil lawsuit filed by the DOJ regarding Medicare Part C risk-adjustment data.
• CMS has notified the company of its intent to impose intermediate sanctions for alleged noncompliance with Medicare Advantage risk adjustment data submission requirements.

Related Party Transactions

• Related party transactions with Mosaic Health included care delivery and enablement services amounting to $193 million for the three months ended March 31, 2026.
• Related party transactions with Liberty Dental included administrative services for Medicare Advantage members amounting to $133 million for the three months ended March 31, 2026.

Stakeholder Impact

• Shareholders may be impacted by the decrease in net income and EPS.
• Members may experience changes in coverage or costs due to regulatory shifts and evolving business strategies.
• Employees may be affected by the Operating Model Transformation Program, which includes targeted workforce reductions and role realignments.
• Providers may be impacted by changes in contracting opportunities and prompt pay commitments resulting from the Provider Settlement Agreement.

Next Steps

• Continue to work with CMS to complete steps required to avoid sanctions related to Medicare Advantage risk adjustment data submission.
• Vigorously defend against ongoing follow-on cases related to the BCBSA Litigation.
• Implement initiatives under the 2026-2027 Operating Model Transformation Program, including streamlining decision-making, simplifying organizational structures, and enhancing technology use.
• Continue to monitor and adapt to regulatory changes and their impact on business operations.
• Manage medical cost trends through various medical management programs and benefit design changes.
• Evaluate the impact of the expiration of enhanced PTCs on Individual market enrollment.

Key Dates

Recommendation

While revenue growth is positive, the significant decrease in net income and EPS, coupled with rising operating expenses and membership declines in key segments, warrants a cautious approach. The ongoing legal and regulatory challenges, particularly the CMS sanctions and the Medicare risk adjustment accrual, introduce considerable uncertainty. The company's strategic transformation efforts and improved Medicare Star Ratings are positive, but the near-term financial performance and contingent liabilities suggest a 'hold' recommendation until greater clarity emerges on these issues.

Keywords

Elevance Health, Form 10-Q, Quarterly Report, Health Insurance, Medicare, Medicaid, Financial Results, Operating Revenue, Net Income, Earnings Per Share, Medical Membership, Healthcare Services, CarelonRx, Carelon Services, Risk Adjustment, Litigation